Life sciences investment firm Perceptive Advisors significantly reduced its holdings in ABIVAX SA (ABVX) during the second quarter of 2026, cutting its position by over 77%. The firm sold an estimated 254,880 shares, decreasing its total stake from 328,880 to just 74,000 shares, according to its latest quarterly disclosure with the SEC.
This filing reflects trading activity that occurred between April 1 and June 30, 2026. During that period, ABIVAX, a clinical-stage biotech company, released updated safety data for its ulcerative colitis drug, obefazimod, which eased previous market concerns over its safety profile. The company was also preparing for a New Drug Application with the FDA for obefazimod, with topline results from its Phase 3 maintenance trial expected late in the quarter.